Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemfibrozil adjunctive therapy for obsessive-compulsive disorder
IRCT20230211057389N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gemfibrozil in obsessive compulsive disorder (OCD) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoint: Yale-Brown Obsessive Compulsive Scale. Started Dec 2023; status: completed.
02
Drugs
gemfibrozil
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20230211057389N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230211057389N1.